This is ELIMOX
ELIMOX, Biopharmaceutical therapy for treatment of Primary Hyperoxaluria, is a project funded by FP7-SME-2013 Research for the benefit of SMEs program. The project is co-ordinated by OxThera AB, Stockholm, Sweden.
The ELIMOX Consortium has three SME-partners; OxThera AB, Cobra Biologics Ltd and SymbioPharma AG; and nine RTD-partners; ErgoMed Clinical Research Ltd, Universitätsklinik Bonn, Hospices Civils de Lyon, University College London Hospitals, Galenica AB, KABS Laboratories Inc., MVZ Institut für Mikroökologie, TNO and Bio-Images Research Ltd. The project is a truly international project.
This research has received funding from the European Union´s Seventh Framework Programme managed by REA-Research Executive Agency http://ec.europa.eu/research/rea (FP7/2007-2013) under grant agreement no FP7-SME-2013.
About Primary Hyperoxaluria
Primary Hyperoxaluria (PH) is a rare autosomal recessive inborn error of glyoxylate metabolism, with a prevalence of 1-3 per million. The disease is characterised by severe hyperoxaluria, i.e. excessively high levels of oxalate in the urine of the patient and excessively high oxalate levels in the plasma of patients suffering from chronic renal failure. The disease is present at birth, and most patients develop kidney stones and nephrocalcinosis at very young ages, most often under the age of 10.
Progression of renal failure is followed by systemic deposition of CaOx and premature death. Overall, the risk of end-stage renal disease (ESRD) is 50% by age 15 and 80% by age 30. The median age at death is around 30. (Hoppe et al., 2009). There is currently no approved pharmaceutical therapy for this devastating disease. The only curative therapy, applicable for PH type I, is eventually a combined kidney and liver transplantation at end stage renal disease (Hoppe, 2009).
There are no existing anticipated business agreements which may impose limitations on the subsequent exploitation or information or inventions generated as a result of the project.
- OxThera AB, Coordinator
- Cobra Biologics Ltd
- SymbioPharm GMBH
- Ergomed Clinical Research Ltd
- Universitätsklinikum Bonn
- Hospices Civils de Lyon
- University College London Hospitals NHS Foundation Trust
- Galenica AB
- K.A.B.S. Laboratories Inc.
- Medizinisches Versorgumszentrum Institut für Mikroökologie
- Nederlandse Organisatie voor Toegepast Naturwetenschappelijk Onderzoek (TNO)
- Bio-Images Research Ltd